. 2022 May 11;16(Suppl 2):ii30–ii41. doi: 10.1093/ecco-jcc/jjac011

Table 2.

Ustekinumab efficacy and safety data from real-life studies

First author	n of pts	Mean age [y]	Male n [%]	Study duration	Study arms	Primary endpoint	Main results	AEs	SAEs
Chaparro¹²	463	45	na	15 months	sc UST 90 mg e8w sc UST 90 mg e12w	Clinical remission at wk 16	56.0% [cumulative UST]	na	na
Straatmijer¹³	252	41	100 [39.7%]	104 weeks	sc UST 90 mg e8w sc UST 90 mg e12w	Corticosteroid-free clinical remission at wk 104	34.0% [cumulative UST]	99 e100py [cumulative UST]	9 e100py [cumulative UST]
Iborra¹⁴	407	45.3	195 [48.0%]	52 weeks	sc UST 90 mg e4w sc UST 90 mg e8w sc UST 90 mg e12w	Clinical remission at wk 52	60.0% 72.0% 89.0%	14.7% [cumulative UST]	na
Bermejo¹⁵	53	45	26 [49.1%]	16 weeks	sc UST 90 mg e4w sc UST 90 mg e8w sc UST 90 mg e12w	Clinical remission at wk 16	43.3% [cumulative UST]	na	1.9%
Fumery¹⁶	100	35	48 [48.0%]	8.2 months	sc UST 90 mg e4w	Corticosteroid-free clinical remission at 6 months	49.0%	12.0%	5.0%

n, number; pts, patients; y, years; AEs, adverse events; SAEs, serious adverse events; UST, ustekinumab; iv, intravenous; PBO, placebo; sc, subcutaneous; e8w, every 8 weeks; e12w,every 12 weeks; wk, week or Week; na, not available; e100py, events per 100 patient-years.